Sera Prognostics Inks $19.3M Series A
Sera Prognostics Inc., a company developing tests to diagnose preterm birth and other pregnancy complications, has raised $19.3 million from a slew of investors including InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners. The Series A financing will help fund clinical trials and the commercial launch of its preterm birth diagnostic test.
15 November 2011•2 mins read
